Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
pharmaceutical investing “We’re Financially Prudent,” Says CFO and President of Knight Therapeutics Samira Sakhia
CannTrust™ Announces Receiving Health Canada Approval to Export Medical Marijuana Internationally and the Shipping of Medical Marijuana to Australia Français
